Supply Chain and Enterprise Risk Management: Navigating the Unknown (Re-engineering the Health Care Supply Chain: A CQO Thought Leader Discussion Series) An AHRMM and ASHRM Joint Presentation

By AHRMM

AHRMM Webinar Image

 

Price: Member: FREE  |  Non-Member: $49.00

CEC Hours: 1

Order Webinar

  

 

Re-engineering the Health Care Supply Chain: A CQO Thought Leader Discussion Series” is hosted by AHRMM's Cost, Quality and Outcomes (CQO) Movement sponsors. This webinar series focuses on how the health care supply chain will evolve and be more resilient in the post-pandemic environment.

As the COVID-19 crisis continues, supply chain and risk management professionals must work closely together to mitigate health care supply chain risks at the global, supplier and product levels.

Join AHRMM and the American Society for Health Care Risk Management (ASHRM), in the fifth and final webinar in AHRMM’s “CQO Thought Leader Discussion Series: Re-engineering the Health Care Supply Chain”. Engage with senior leaders within the finance/supply chain and risk management disciplines who will share their thoughts on the organizational and patient risks related to current vulnerabilities and action planning that health care organizations can take to minimize their exposure to these risks. Key takeaways include ERM frameworks and cost verses risk mitigation strategies.

 

Panelists:

  • Barbara McCarthy, Health Enterprise Risk Officer, Beverly Hospital
  • Mary Beth Briscoe, former CFO and Health Care Supply Chain Executive, AHRMM Board Member
  • Mike Schiller, Senior Director, AHRM

 

Sponsored By:

CQO Sponsors

Related Resources

Case Studies
The following leading practice describes methods used to reduce Hospital Acquired Pressure Ulcers (HAPU).
Case Studies
AHRMM is developing a repository for leading and proven supply chain practices, case studies, and toolkits that are developed from a
Toolkits/Methodology
The Institute for Healthcare Im
White Papers
This white paper explores the realities facing healthcare delivery, some of the new models being developed and what they could mean for the s
Letter/Comment
AHRMM comments to the FDA regarding an amendment to the UDI proposed rule to address the UDI implementation time frame required by the 2012 Fo